rituximab

noun

ri·​tux·​i·​mab ri-ˈtək-si-ˌmab 

: a genetically engineered monoclonal antibody that is administered by intravenous injection especially to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia by binding to a receptor found on the surface of B cells and causing their lysis

Note: Rixtuximab is a chimeric monoclonal antibody prepared from humans and mice. It is marketed under the trademark Rituxan.